what this node claims
AlphaFold metrics / MTNR1A
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
54%
low debt pressure
21%
86%structurestrong
pLDDT 85.73
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 85.73
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 85.73
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
350 residues / min 31.48 / max 98.56 / source alphafold db
Very high
68.3%
239 residues / >=90
Confident
14.9%
52 residues / 70-89
Low
6.3%
22 residues / 50-69
Very low
10.6%
37 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 350 of 350 residues.
- residues 318-350 / mean 51.52
- residues 1-21 / mean 39.9
- residues 225-228 / mean 64.66
- residues 223-223 / mean 66.19
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.